Back to top

Image: Bigstock

Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics

Read MoreHide Full Article

For the quarter ended December 2025, Cardinal Health (CAH - Free Report) reported revenue of $65.63 billion, up 18.8% over the same period last year. EPS came in at $2.63, compared to $1.93 in the year-ago quarter.

The reported revenue represents a surprise of +0.9% over the Zacks Consensus Estimate of $65.04 billion. With the consensus EPS estimate being $2.39, the EPS surprise was +9.86%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Revenue- Pharmaceutical and Specialty Solutions: $60.67 billion versus $59.01 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.3% change.
  • Revenue- Other: $1.72 billion compared to the $1.64 billion average estimate based on four analysts. The reported number represents a change of +34.4% year over year.
  • Revenue- Medical Products and Distribution: $3.26 billion versus the four-analyst average estimate of $3.28 billion. The reported number represents a year-over-year change of +3.3%.
  • Segment profit- Pharmaceutical and Specialty Solutions: $687 million versus the four-analyst average estimate of $639.5 million.
  • Segment profit- Other: $179 million compared to the $157.26 million average estimate based on four analysts.
  • Segment profit- Global Medical Products and Distribution: $37 million versus $15.85 million estimated by four analysts on average.

View all Key Company Metrics for Cardinal here>>>

Shares of Cardinal have returned -0.2% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Cardinal Health, Inc. (CAH) - free report >>

Published in